With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...

Chief Executive David Ricks told then-UK Health Secretary Victoria Atkins last December that the company’s new Alzheimer’s ...

Drugmaker Eli Lilly signed an agreement with the U.K. government to support early-stage life sciences businesses in the country. As part of the collaboration, which was announced Monday at the U.K.'s ...

On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...

Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...

Eli Lilly’s Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first ...

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ...

However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly’s next twelve months forward P/E ratio, investors are paying ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s ...